Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

ON 01910.Na Suppresses Cyclin D1 Accumulation in trisomy 8 Myelodysplastic Syndromes Patients While Decreasing Bone Marrow CD34+ Blast Counts and Aneuploid Clone Size.

Elaine M Sloand, MD, Matthew J. Olnes, MD, PhD, Naomi Galili, PhD, Aarthi Shenoy, MD, Loretta Pfannes, Francois Wilhelm, MD, Ph.D, Barbara Weinstein, Phillip Scheinberg, MD, Jerome E. Groopman, MD, Azra Raza

Blood (2009) 114 (22): 120.

https://doi.org/10.1182/blood.V114.22.120.120

Published: 2009

Journal Articles

Initial Evaluation of a 48-h Continuous Intravenous Infusion Weekly Regimen of ON 01910.Na in Advanced Myelodysplastic Syndrome (MDS).

Azra Raza, MD, Naomi Galili, PhD, Muhammad Shahzad Ali, MD, Fahad Ali, MD, Alyssa Goodman, Samir Ahmed Qasim, MD, Francois Wilhelm, MD, Ph.D

Blood (2009) 114 (22): 3815.

https://doi.org/10.1182/blood.V114.22.3815.3815

Published: 2009

Journal Articles

Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na, A Novel Clinical Trial Stage Compound.

David M. Soper, PhD, Ying-Wen Huang, MS, Francois Wilhelm, MD, Ph.D, S. C. Cosenza, E. Premkumar Reddy, PhD, Alessandra Cesano, MD, PhD, Peter L Greenberg, MD, Wendy J. Fantl, PhD

Blood (2009) 114 (22): 3827.

https://doi.org/10.1182/blood.V114.22.3827.3827

Published: 2009

Journal Articles

Effects of a Novel Benzyl Styryl Sulfone Derivative ON 01910.Na On the Myelodysplastic Syndrome (MDS) Derived Clone in Patients Relapsing Following Response to Azacitidine (AzaC) Therapy.

Lewis R. Silverman, MD, Rosalie Odchimar-Reissig, Shyamala C. Navada, MD, Takao Ohnuma, MD, Vesna Najfeld, Ph.D., Francois Wilhelm, MD, Ph.D, E. Premkumar Reddy, PhD, James F Holland

Blood (2009) 114 (22): 4839.

https://doi.org/10.1182/blood.V114.22.4839.4839

Published: 2009

Journal Articles

Suppression of Cyclin D 1 (CD1) by on 01910.Na Is Associated with Decreased Survival or Trisomy 8 Myelodysplastic Bone Marrow: A Potential Targetted Therapy for Trisomy 8 MDS.

Aarthi Shenoy, MD, Loretta Pfannes, Francois Wilhelm, MD, Ph.D, Manoj Maniar, Ph.D, Neal Young, MD, Elaine M Sloand, MD

Blood (2008) 112 (11): 1651.

https://doi.org/10.1182/blood.V112.11.1651.1651

Published: 2008

NARROW

ON 01910.Na Suppresses Cyclin D1 Accumulation in trisomy 8 Myelodysplastic Syndromes Patients While Decreasing Bone Marrow CD34+ Blast Counts and Aneuploid Clone Size.

Initial Evaluation of a 48-h Continuous Intravenous Infusion Weekly Regimen of ON 01910.Na in Advanced Myelodysplastic Syndrome (MDS).

Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na, A Novel Clinical Trial Stage Compound.

Effects of a Novel Benzyl Styryl Sulfone Derivative ON 01910.Na On the Myelodysplastic Syndrome (MDS) Derived Clone in Patients Relapsing Following Response to Azacitidine (AzaC) Therapy.

Suppression of Cyclin D 1 (CD1) by on 01910.Na Is Associated with Decreased Survival or Trisomy 8 Myelodysplastic Bone Marrow: A Potential Targetted Therapy for Trisomy 8 MDS.

Email alerts

ASH Publications

American Society of Hematology

ON 01910.Na Suppresses Cyclin D1 Accumulation in trisomy 8 Myelodysplastic Syndromes Patients While Decreasing Bone Marrow CD34+ Blast Counts and Aneuploid Clone Size.

Initial Evaluation of a 48-h Continuous Intravenous Infusion Weekly Regimen of ON 01910.Na in Advanced Myelodysplastic Syndrome (MDS).

Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na, A Novel Clinical Trial Stage Compound.

Effects of a Novel Benzyl Styryl Sulfone Derivative ON 01910.Na On the Myelodysplastic Syndrome (MDS) Derived Clone in Patients Relapsing Following Response to Azacitidine (AzaC) Therapy.

Suppression of Cyclin D 1 (CD1) by on 01910.Na Is Associated with Decreased Survival or Trisomy 8 Myelodysplastic Bone Marrow: A Potential Targetted Therapy for Trisomy 8 MDS.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only